Core Viewpoint - The successful completion of the first robot-assisted percutaneous coronary intervention (PCI) at Beijing Friendship Hospital's Shunyi District marks a significant advancement in the field of cardiovascular intervention and showcases the hospital's leadership in smart medical technology [2][7]. Group 1: Procedure Details - A 65-year-old male patient diagnosed with coronary heart disease and unstable angina underwent the procedure, which involved severe stenosis in the circumflex artery and was completed in just 20 minutes [2][4]. - The procedure utilized a vascular intervention control system, allowing for remote operation and precise control during the stent placement, resulting in the complete resolution of the stenosis [4][5]. Group 2: Technological Innovation - The vascular intervention control system, developed by a startup incubated by the Chinese Academy of Sciences, is the first of its kind in China to provide multi-channel assistance throughout the procedure, significantly enhancing safety and precision [8][9]. - This system allows operators to perform procedures from a shielded control room, avoiding X-ray exposure, and improves operational comfort and decision-making during surgery [8][9]. Group 3: Clinical and Industry Impact - The successful implementation of this technology not only offers safer and more precise treatment options for cardiovascular patients but also promotes the innovation and clinical application of high-end medical devices in China [9]. - The hospital aims to continue enhancing patient-centered services and accelerate the translation of medical-engineering collaborative results to contribute to the health of the nation [9].

Core Insights - The article discusses the registration and quality management system assessments for medical devices in Guangdong Province, highlighting various companies and their products that have undergone evaluations and received approvals or required modifications [2][5]. Group 1: Company Registrations - Guangdong Weinuodun Medical Technology Co., Ltd. received approval for its medical ozone therapy device on November 3, 2025 [3]. - Guangdong Baisheng Medical Instrument Co., Ltd. passed the evaluation for high-frequency surgical equipment on November 3, 2025 [3]. - Shenzhen Kefu Biotechnology Co., Ltd. was approved for its continuous glucose monitoring system on November 4, 2025 [3]. - Guangzhou Wanfu Biological Technology Co., Ltd. received approval for its hepatitis B virus nucleic acid testing kit on November 10, 2025 [3]. - Shenzhen Karman Medical Equipment Co., Ltd. was approved for its intracranial pressure sensor and cerebrospinal fluid drainage set on November 12, 2025 [3]. Group 2: Quality Management System Assessments - The Guangdong Provincial Drug Administration is implementing a quality management system assessment for Class II medical devices, with results communicated to applicants via SMS or web queries since May 2022 [5]. - Companies such as Shenzhen Aibo Hechuang Medical Robot Co., Ltd. received approval for their vascular intervention surgery control system on November 27, 2025 [5]. - Guangdong Tiancheng Tianmei Medical Technology Co., Ltd. was approved for absorbable surgical sutures on November 19, 2025 [4].